Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial

Laurène Fenwarth; Nicolas Duployez; Alice Marceau-Renaut; Wadih Abou Chahla; Stéphane Ducassou; Virginie Gandemer; Marlène Pasquet; Thierry Leblanc; Pascale Schneider; Carine Domenech; Paul Saultier; Guy Leverger; Hélène Lapillonne; Claude Preudhomme; Arnaud Petit

doi:10.3324/haematol.2020.248872

Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial

Haematologica. 2021 Mar 1;106(3):908-912. doi: 10.3324/haematol.2020.248872.

Authors

Affiliations

¹ Laboratory of Hematology, CHU Lille, INSERM UMR-S 1277 - 9020 CNRS, Lille
² Pediatric Hematology Department, CHU Lille, Lille
³ Pediatric Hematology and Oncology Department, CHU Bordeaux, Bordeaux
⁴ Pediatric Hematology and Oncology Department, CHU Rennes, Rennes
⁵ Pediatric Hematology and Immunology Department, CHU Toulouse, Toulouse
⁶ Pediatric Hematology Department, AP-HP Robert Debré Hospital, Paris
⁷ Pediatric Hematology Department, CHU Rouen, Rouen
⁸ Institute of Hematology and Pediatric Oncology, Lyon 1 University, Hospices Civils de Lyon, Lyon
⁹ Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, APHM and Aix-Marseille University, Marseille
¹⁰ Pediatric Hematology and Oncology Department, Armand Trousseau Hospital, AP-HP, Sorbonne University, UMRS_938, CONECTAML, Paris
¹¹ Laboratory of Hematology, Armand Trousseau Hospital, Sorbonne University, UMRS_938, CONECT-AML, Paris, France

No abstract available

Publication types

Letter

MeSH terms

Child
Disease Susceptibility
Genetic Predisposition to Disease
Germ Cells
Germ-Line Mutation
Humans
Leukemia, Myeloid, Acute* / epidemiology
Leukemia, Myeloid, Acute* / genetics
Transcription Factors*

Substances

Transcription Factors

Grants and funding

Funding: the ELAM02 trial was supported by a grant from the French Ministry of Health (PRTK 2012-43-CARAMELE). CONECT-AML (COllaborative Network for Children and Teenagers with Acute Myeloid Leukemia) is supported by a grant from InCA, Fondation ARC, Ligue nationale contre le cancer, and Laurette Fugain (InCa-ARC-LIGUE_11905).